142 related articles for article (PubMed ID: 23549020)
1. Leptomeningeal metastasis from prostate cancer.
Cante D; Franco P; Sciacero P; Girelli G; Casanova Borca V; Pasquino M; Migliaccio F; Tofani S; Grassi L; Marra A; Ozzello F; La Porta MR; Ricardi U
Tumori; 2013; 99(1):6e-10e. PubMed ID: 23549020
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review.
Cone LA; Koochek K; Henager HA; Fausel R; Gade-Andavolu R; Potts BE; Jennings LM
Surg Neurol; 2006 Apr; 65(4):372-5, discussion 375-6. PubMed ID: 16531199
[TBL] [Abstract][Full Text] [Related]
3. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Okoye E; Choi EK; Divatia M; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(12):9061-6. PubMed ID: 25674288
[TBL] [Abstract][Full Text] [Related]
4. Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus.
Cante D; Franco P; Sciacero P; Girelli GF; Casanova Borca V; Pasquino M; Tofani S; Bombaci S; Migliaccio F; Marra A; Numico G; La Porta MR; Ricardi U
Tumori; 2013; 99(2):e80-3. PubMed ID: 23748836
[TBL] [Abstract][Full Text] [Related]
5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease.
Orphanos G; Ioannidis G; Michael M; Kitrou G
Med Oncol; 2009; 26(2):143-6. PubMed ID: 18830829
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal involvement by prostate carcinoma an ominous head of a well-known Hydra.
Tawadros F; Manthri S; Zayko M; Chakraborty K
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527212
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
11. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
17. New approaches to and current treatment of leptomeningeal metastases.
Chamberlain MC
Curr Opin Neurol; 1994 Dec; 7(6):492-500. PubMed ID: 7532525
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.
Kawahara T; Miyoshi Y; Sekiguchi Z; Sano F; Hayashi N; Teranishi J; Misaki H; Noguchi K; Kubota Y; Uemura H
PLoS One; 2012; 7(10):e48186. PubMed ID: 23118948
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
